Stocks › RLMD
RELMADA THERAPEUTICS, INC.
RLMD·Nasdaq·
United States·USD
United States·USD$3.28
-0.20 (-5.75%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
RLMD
RELMADA THERAPEUTICS, INC. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
RLMDS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of RLMD by members of U.S. Congress · 2 on record
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
 Christopher L. JacobsHouse · R · NY |
RLMDRELMADA THERAPEUTICS, INC. · Stock |
Sale $1,001 - $15,000 |
Jan 20, 2023 | Dec 12, 2022 | Filing ↗ |
| Christopher L. JacobsHouse · R · NY |
RLMDRELMADA THERAPEUTICS, INC. · Stock |
Purchase $1,001 - $15,000 |
Dec 12, 2022 | Nov 8, 2022 | Filing ↗ |
Whale Activity
Position changes in RLMD reported for 2026-06-30 by 11 tracked institutional filers
- Increased2
- New3
- Held0
- Decreased3
- Closed1
- No prior filing2
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 7.4M | $51.4M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.5M | $30.9M | increased |
| MILLENNIUM MANAGEMENT LLC | 2.4M | $16.3M | decreased |
| CITADEL ADVISORS LLC | 1.1M | $7.3M | new |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 898.2K | $6.2M | new |
| Knott David M Jr | 451.0K | $3.1M | — |
| Seven Fleet Capital Management LP | 348.3K | $2.4M | — |
| TWO SIGMA INVESTMENTS, LP | 214.9K | $1.5M | decreased |
| D. E. Shaw & Co., Inc. | 109.5K | $758K | new |
| RENAISSANCE TECHNOLOGIES LLC | 57.8K | $400K | decreased |
| Point72 Asset Management | 0 | $0 | closed |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by RLMD insiders, by quarter · Form 4
Recent Insider Transactions
227 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Shenouda MagedChief Financial Officer | Purchase | +79.8K | $4.25 | $339K | Sep 10, 2026 | Form 4 ↗ |
| TRAVERSA SERGIOChief Executive Officer · Director | Purchase | +100.0K | $4.10 | $410K | Sep 10, 2026 | Form 4 ↗ |
| Shenouda MagedChief Financial Officer | Purchase | +120.2K | $4.20 | $505K | Sep 9, 2026 | Form 4 ↗ |
| TRAVERSA SERGIOChief Executive Officer · Director | Purchase | +100.0K | $4.18 | $418K | Sep 9, 2026 | Form 4 ↗ |
| TRAVERSA SERGIOChief Executive Officer · Director | Purchase | +27.5K | $4.12 | $113K | Dec 15, 2025 | Form 4 ↗ |
| Shenouda MagedChief Financial Officer | Purchase | +11.7K | $4.12 | $48K | Dec 15, 2025 | Form 4 ↗ |
| Ence ChuckCAO and COO | Purchase | +136.0K | $2.20 | $299K | Nov 5, 2025 | Form 4 ↗ |
| TRAVERSA SERGIOChief Executive Officer · Director | Purchase | +272.5K | $2.20 | $600K | Nov 5, 2025 | Form 4 ↗ |
| Shenouda MagedChief Financial Officer | Purchase | +500.0K | $2.20 | $1.1M | Nov 5, 2025 | Form 4 ↗ |
| Kelly Paul EdwardChief Operating Officer · Director | Purchase | +90.0K | $2.20 | $198K | Nov 5, 2025 | Form 4 ↗ |
| TRAVERSA SERGIOChief Executive Officer · Director | Purchase | +56.0K | $0.74 | $41K | Aug 28, 2025 | Form 4 ↗ |
| TRAVERSA SERGIOChief Executive Officer · Director | Purchase | +129.5K | $0.67 | $87K | Aug 27, 2025 | Form 4 ↗ |
| TRAVERSA SERGIOChief Executive Officer · Director | Purchase | +80.5K | $0.62 | $50K | Aug 26, 2025 | Form 4 ↗ |
| Shenouda MagedChief Financial Officer | Purchase | +60.0K | $0.52 | $31K | May 20, 2025 | Form 4 ↗ |
| TRAVERSA SERGIOChief Executive Officer · Director | Purchase | +147.7K | $0.56 | $83K | May 20, 2025 | Form 4 ↗ |
| Shenouda MagedChief Financial Officer | Purchase | +90.0K | $0.49 | $44K | May 19, 2025 | Form 4 ↗ |
| TRAVERSA SERGIOChief Executive Officer · Director | Purchase | +30.0K | $0.50 | $15K | May 19, 2025 | Form 4 ↗ |
| Kelly Paul EdwardChief Operating Officer · Director | Purchase | +200.0K | $0.43 | $86K | May 16, 2025 | Form 4 ↗ |
| Shenouda MagedChief Financial Officer | Purchase | +50.0K | $0.44 | $22K | May 16, 2025 | Form 4 ↗ |
| Ence ChuckCA and CO | Purchase | +229.0K | $0.45 | $103K | May 16, 2025 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding RLMD · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 3.2M | $21.9M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 2.1M | $14.4M | 0.02% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.2M | $8.3M | 0.01% | Jun 30, 2026 |
| Eventide Healthcare & Life Sciences Fund MUTUAL FUND SERIES TRUST | 1.0M | $7.0M | 0.39% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF iShares Trust | 865.6K | $6.0M | 0.04% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 1.0M | $5.5M | 0.02% | Jul 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF SPDR SERIES TRUST | 655.1K | $4.5M | 1.06% | Jun 30, 2026 |
| Franklin Biotechnology Discovery Fund Franklin Strategic Series | 788.7K | $4.2M | 0.36% | Jul 31, 2026 |
| AdvisorShares Psychedelics ETF AdvisorShares Trust | 438.9K | $3.0M | 6.84% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 379.2K | $2.7M | 0.01% | May 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list RLMD's shares (CUSIP 75955J402), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- William BlankSCHEDULE 13G/A · passive (13G) · 7.3M shares7.0%
Aug 14, 2026 · ↗ - Matthew SesterhennSCHEDULE 13G/A · passive (13G) · 7.3M shares7.0%
Aug 14, 2026 · ↗ - Squadron Capital Management LLCSCHEDULE 13G/A · passive (13G) · 7.3M shares7.0%
Aug 14, 2026 · ↗ - Squadron Master Fund LPSCHEDULE 13G/A · passive (13G) · 7.3M shares7.0%
Aug 14, 2026 · ↗ - BlackRock, Inc.SCHEDULE 13G · passive (13G) · 7.4M shares7.0%
Jul 29, 2026 · ↗ - Israel A. EnglanderSCHEDULE 13G · passive (13G) · 4.6M shares4.4%
Jun 22, 2026 · ↗ - Millennium Group Management LLCSCHEDULE 13G · passive (13G) · 4.6M shares4.4%
Jun 22, 2026 · ↗ - Millennium Management LLCSCHEDULE 13G · passive (13G) · 4.6M shares4.4%
Jun 22, 2026 · ↗ - Bong Y. KohSCHEDULE 13G · passive (13G) · 6.5M shares6.2%
Jun 9, 2026 · ↗ - Nimish ShahSCHEDULE 13G · passive (13G) · 6.5M shares6.2%
Jun 9, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming relmada therapeutics as client
No lobbying filings found naming RELMADA THERAPEUTICS, INC. as the client.
- THE KPM GROUP DC LLCRELMADA THERAPEUTICS, INC. · 2022 Q4$30K
Filing ↗ - THE KPM GROUP DC LLCRELMADA THERAPEUTICS, INC. · 2022 Q3$30K
Filing ↗ - THE KPM GROUP DC LLCRELMADA THERAPEUTICS, INC. · 2022 Q2$20K
Filing ↗ - THE KPM GROUP DC LLCRELMADA THERAPEUTICS, INC. · 2022 Q1$20K
Filing ↗ - THE KPM GROUP DC LLCRELMADA THERAPEUTICS, INC. · 2021 Q4$30K
Filing ↗
Government Contracts
Federal awards to RELMADA THERAPEUTICS, INC. · USAspending
No federal contract awards found for RELMADA THERAPEUTICS, INC..
U.S. Patents
Recent USPTO applications naming RELMADA THERAPEUTICS, INC.
No USPTO patent applications found for RELMADA THERAPEUTICS, INC..
Annual Financials
From RLMD's 10-K filings · XBRL
No annual XBRL figures on record for RLMD. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
- 1-for-4Reverse splitSep 30, 2019
- 1-for-5Reverse splitAug 12, 2015
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 8.01Other eventsSep 8, 2026
EDGAR ↗ - 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureAug 6, 2026
EDGAR ↗ - 8-K · Items 7.01, 9.01Reg FD disclosureJul 28, 2026
EDGAR ↗ - 8-K · Items 5.03, 5.07, 9.01Bylaw amendment · Shareholder voteMay 28, 2026
EDGAR ↗ - 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureMay 12, 2026
EDGAR ↗
About RELMADA THERAPEUTICS, INC.
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersCORAL GABLES, FL
IncorporatedNV
SEC CIK0001553643 ↗
Former namesCAMP NINE, INC.